Cancer Clinical Investigation

The goal of the Cancer Clinical Investigation (CCI) Program is to leverage the TCI’s pioneering science to maximally impact cancer treatment through the preclinical and clinical development of cutting-edge treatment strategies. CCI members, through their complementary and synergistic expertise, work to identify novel therapeutic strategies and advance TCI discoveries from the laboratory to the clinic and back, leading to constant cycles of scientific innovation. In addition to translating research that is initiated from within the Program, the CCI program is responsible for translating the science that emerges from other programs into novel therapeutic approaches and clinical trials for cancer patients by collaborating with other TCI Programs.

Program Goals

  • To develop therapies, and associated biomarkers, relevant to cancer cell-intrinsic processes
  • To develop therapies, and associated biomarkers, relevant to the host immune system and the tumor microenvironment

Cancer Clinical Investigation Research Program Leaders

Matthew Galsky, MD
Matthew Galsky, MD

Associate Director, Translational Research

Jian Jin, PhD
Jian Jin, PhD

Professor, Therapeutics Discovery, Oncological Sciences, Pharmacological Sciences, Neuroscience
Director, Mount Sinai Center for Therapeutics Discovery

Samir Parekh, MBBS
Samir Parekh, MBBS

Professor, Medicine (Hematology and Medical Oncology), and Oncological Sciences, and Immunology and Immunotherapy
Director, Translational Research in Multiple Myeloma

Moving the Field Forward

Find out how we collaborate to address cancer’s most complex challenges.

Stuart A. Aaronson, MD: 2024 Jacobi Medallion Recipient
Watch Videos

Contact Us